Thus, in the combination group, the preserved bone mass was observed despite a weight reduction of a magnitude that is clinically relevant in the context of novel incretin-based obesity therapies, such as semaglutide and tirzepatide, which resulted in weight losses of around 15% to 19% in a systematic review.47 The gene discussed is GCG; the disease is Obesity.